Is chemoradiotherapy worth it in metastatic seminoma as first-line treatment? - Authors' reply
Lancet Oncol
.
2023 Feb;24(2):e66.
doi: 10.1016/S1470-2045(22)00791-4.
Authors
Alexandros Papachristofilou
1
,
Stefanie Hayoz
2
,
Richard Cathomas
3
Affiliations
1
Department of Radiation Oncology, University Hospital of Basel, 4031 Basel, Switzerland. Electronic address: alexandros.papachristofilou@usb.ch.
2
Competence Center of SAKK-Swiss Group for Clinical Cancer Research, Bern, Switzerland.
3
Division of Oncology/Haematology, Kantonsspital Graubünden, Chur, Switzerland.
PMID:
36725146
DOI:
10.1016/S1470-2045(22)00791-4
No abstract available
Publication types
Letter
Comment
MeSH terms
Chemoradiotherapy
Humans
Male
Neoplasms, Germ Cell and Embryonal*
Neoplasms, Second Primary*
Seminoma* / drug therapy
Seminoma* / secondary
Testicular Neoplasms* / drug therapy
Testicular Neoplasms* / radiotherapy